Open for inclusion

A randomized phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumor (GIST)

Cancer type: Gastric cancer

Phase: II

Principal Investigator: Joensuu Heikki

Country: FI

Keywords: Finland, Helsinki,

Status: Open for inclusion